{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:45:41Z","timestamp":1787953541148,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) symptoms are often encountered in patients after transurethral resection of the prostate (TUR-P) or transurethral incision of the prostate (TUI-P) for benign prostatic obstruction (BPO). Either antimuscarinics or b-3 agonist has been found effective in relieving OAB symptoms. However, urologists usually do not prescribe such medication immediately after TUR-P or TUI-P to avoid an increase in postvoid residual and risk of urinary tract infection. If OAB medication can be used and adverse events (AEs) can be reduced to minimum, patients\u2019 quality of life after bladder outlet obstruction surgery could be improved. This study compared the safety and efficacy between solifenacin and mirabegron in men undergoing TUR-P or TUI-P.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This prospective, randomized trial compared the safety and efficacy of OAB medication on the reduction in Urgency Severity Score (USS), OAB Symptoms Score (OABSS), International Prostate Symptom Score, and urgency urinary incontinence episodes in men with BPO undergoing surgical intervention. All patients could void smoothly after catheter removal and were randomly received daily solifenacin 5 mg, mirabegron 50 mg, or no interventions for 4 weeks. At 2 and 4 weeks postoperatively, participants\u2019 OAB symptoms and AEs were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 57 men were enrolled in this study with a mean age of 70.8 \u00b1 6.1 years. At 2 weeks postoperatively, USS (1.56 \u00b1 1.72 vs. 2.39 \u00b1 1.72 vs. 2.26 \u00b1 1.73,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.011) and OABSS (5.33 \u00b1 3.65 vs. 7.67 \u00b1 4.19 vs. 8.58 \u00b1 4.31,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.000) were significantly reduced in patients taking solifenacin, mirabegron, or control, respectively. Two patients in the solifenacin group developed urinary retention. However, the changes of variables at 4 weeks postoperatively were insignificant among the three groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Solifenacin and mirabegron are two different drug classes both equally effective in treating immediate OAB symptoms after TUR-P or TUI-P. However, OAB symptoms could be relieved at 4 weeks without any medication. Considering AEs, b-3 agonist has a more favorable safety profile than antimuscarinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_123_23","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T07:10:28Z","timestamp":1692688228000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia \u2013 Which medication to choose?"],"prefix":"10.4103","author":[{"given":"Cheng-Ling","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1442-2042.2006.01589.x","article-title":"Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity?","volume":"13","author":"Tanaka","year":"2006","journal-title":"Int J Urol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.eururo.2005.12.042","article-title":"Complications of transurethral resection of the prostate (TURP) \u2013 Incidence, management, and prevention","volume":"50","author":"Rassweiler","year":"2006","journal-title":"Eur Urol"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","article-title":"Morbidity, mortality and early outcome of transurethral resection of the prostate:A prospective multicenter evaluation of 10,654 patients","volume":"180","author":"Reich","year":"2008","journal-title":"J Urol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/nau.24158","article-title":"Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature","volume":"38","author":"Kasman","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"R896","DOI":"10.1152\/ajpregu.00046.2011","article-title":"Persistent detrusor overactivity in rats after relief of partial urethral obstruction","volume":"301","author":"Jin","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11884-016-0376-1","article-title":"Evaluation and management of lower urinary tract symptoms after outlet surgery for benign prostatic hyperplasia","volume":"11","author":"Singla","year":"2016","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"F388","DOI":"10.1152\/ajprenal.00178.2019","article-title":"Detrusor contractility to parasympathetic mediators is differentially altered in the compensated and decompensated states of diabetic bladder dysfunction","volume":"317","author":"Klee","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1067\/mob.2003.353","article-title":"Proceedings of the national institute of diabetes and digestive and kidney diseases international symposium on epidemiologic issues in urinary incontinence in women","volume":"188","author":"Brown","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005392-199502000-00013","article-title":"Urodynamic findings in patients with diabetic cystopathy","volume":"153","author":"Kaplan","year":"1995","journal-title":"J Urol"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.urology.2014.04.027","article-title":"Factors associated with continuing medical therapy after transurethral resection of prostate","volume":"84","author":"Han","year":"2014","journal-title":"Urology"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: An update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"R15-20240828","first-page":"1660","article-title":"Clinical optimal dose of solifenacin succinate for nursing patients after transurethral resection of the prostate during the perioperative period","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1172\/JCI134892","article-title":"The \u03b23-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans","volume":"130","author":"Finlin","year":"2020","journal-title":"J Clin Invest"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: Efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4111\/kju.2014.55.4.260","article-title":"Tolterodine to relieve urinary symptoms following transurethral resection of the prostate: A double-blind placebo-controlled randomized clinical trial","volume":"55","author":"Tehranchi","year":"2014","journal-title":"Korean J Urol"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_123_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:29:07Z","timestamp":1786724947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_123_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_123_23","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"2023-05-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}